{"id":6587,"date":"2024-01-24T11:22:03","date_gmt":"2024-01-24T03:22:03","guid":{"rendered":"https:\/\/www.umtradings.com\/?p=6473"},"modified":"2024-02-05T01:25:54","modified_gmt":"2024-02-05T01:25:54","slug":"johnson-johnson-exceeds-quarterly-sales-expectations-maintains-outlook","status":"publish","type":"post","link":"https:\/\/www.umtradings.com\/th\/johnson-johnson-exceeds-quarterly-sales-expectations-maintains-outlook\/","title":{"rendered":"Johnson & Johnson Beats Q4 Sales Expectations, Expand More"},"content":{"rendered":"\n

Johnson & Johnson Exceeds Quarterly Sales Expectations, Maintains Outlook<\/strong><\/h1>\n\n\n\n

Johnson & Johnson (JNJ.US)<\/a><\/strong>, a leading pharmaceutical and medical devices company, recently reported its fourth-quarter results, showcasing robust performance that surpassed analyst expectations. The company’s quarterly sales surged to $21.40 billion, accompanied by a net income of $4.13 billion. <\/p>\n\n\n\n

On a per-share basis, net earnings reached $1.70, exhibiting significant growth compared to the previous year. Excluding exceptional items, Johnson & Johnson’s adjusted earnings per share stood at $2.29 for the latest quarter.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Business Segments Performance<\/strong><\/h2>\n\n\n\n

Innovative Medicine<\/em><\/strong><\/h3>\n\n\n\n

Johnson & Johnson operates through two primary business segments. Its Innovative Medicine division, which includes the pharmaceuticals segment, witnessed a remarkable revenue increase of 4.2% to $13.7 billion during the quarter.<\/p>\n\n\n\n

MedTech<\/a><\/em><\/strong><\/h3>\n\n\n\n

The company’s MedTech segment, focusing on medical devices, experienced robust growth, with sales surging by 13.3% to $7.7 billion, reflecting strong market demand and product innovation.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Key Developments<\/strong><\/h2>\n\n\n\n

Johnson & Johnson made significant strides in obtaining regulatory approvals for several new treatments, notably including its Balversa drug for bladder cancer. However, challenges loom as its lucrative Stelara medication faces intensifying competition in the European market by mid-2024.<\/p>\n\n\n\n

During an investor call, CEO Joaquin Duato emphasized the company’s strategic focus on growth through acquisitions. Johnson & Johnson remains open to exploring diverse opportunities to bolster its portfolio and market presence.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Outlook and Guidance<\/strong><\/h2>\n\n\n\n

Despite evolving market dynamics, Johnson & Johnson remains optimistic about its full-year 2024 outlook, maintaining guidance consistent with its December forecasts. The company anticipates operational sales growth in the range of 5-6%, translating to revenues between $88.2 billion and $89 billion.<\/p>\n\n\n\n

In terms of earnings, Johnson & Johnson projects adjusted earnings per share (EPS) between $10.55 and $10.75, reflecting a notable increase of 6.4-8.4% compared to the previous year. This guidance aligns closely with the Wall Street consensus estimate of $10.68.<\/p>\n\n\n\n

For more detailed information, you can read Johnson & Johnson’s full earnings report<\/strong><\/a>, Q4 results<\/strong><\/a> on CNBC, or access the financials<\/strong><\/a> on their investor relations page.<\/em><\/p>\n\n\n

\n
\"Johnson\n\t\t\t\n\t\t\t\t\n\t\t\t<\/svg>\n\t\t<\/button><\/figure>\n<\/div>\n\n\n

(Johnson & Johnson Stock Performance Monthly Chart)<\/em><\/p>\n\n\n\n

<\/div>\n\n\n\n

Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

Q: What were Johnson & Johnson’s Q4 earnings?<\/mark><\/strong><\/h3>
\n

A: Johnson & Johnson reported fourth-quarter earnings that exceeded analyst expectations, with sales reaching $21.40 billion and net income of $4.13 billion.<\/p>\n<\/div><\/div>\n\n\n\n

Q: How did Johnson & Johnson’s business segments perform in the latest quarter?<\/mark><\/strong><\/h3>
\n

A: The Innovative Medicine division saw revenue grow by 4.2% to $13.7 billion, while the MedTech segment experienced a robust sales increase of 13.3% to $7.7 billion.<\/p>\n<\/div><\/div>\n\n\n\n

Q: What is Johnson & Johnson’s outlook for the full year 2024?<\/mark><\/strong><\/h3>
\n

A: Johnson & Johnson maintains an optimistic outlook for 2024, projecting operational sales growth of 5-6% and adjusted EPS between $10.55 and $10.75, in line with Wall Street expectations.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n\n\n
<\/div>\n\n\n","protected":false},"excerpt":{"rendered":"

Johnson & Johnson Exceeds Quarterly Sales Expectations, Maintains Outlook Johnson & Johnson (JNJ.US), a leading pharmaceutical and medical devices company, recently reported its fourth-quarter results, showcasing robust performance that surpassed analyst expectations. The company’s quarterly sales surged to $21.40 billion, accompanied by a net income of $4.13 billion. On a per-share basis, net earnings reached […]<\/p>\n","protected":false},"author":13,"featured_media":6681,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2,3],"tags":[120,121],"class_list":["post-6587","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market_news","category-latest","tag-jnj-us","tag-johnson-johnson"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/posts\/6587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/comments?post=6587"}],"version-history":[{"count":0,"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/posts\/6587\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/media\/6681"}],"wp:attachment":[{"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/media?parent=6587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/categories?post=6587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.umtradings.com\/th\/wp-json\/wp\/v2\/tags?post=6587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}